Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
itacitinib + calcineurin inhibitor
- Development stage
- Unknown
- Lead developer
- Incyte
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Itacitinib + calcineurin inhibitor is an investigational combination therapy consisting of itacitinib, a selective Janus kinase 1 (JAK1) inhibitor, and a calcineurin inhibitor (CNI, such as tacrolimus or cyclosporine). Itacitinib suppresses the JAK-STAT signaling pathway involved in immune activation, while calcineurin inhibitors block the phosphatase activity of calcineurin, thereby inhibiting T-cell activation and cytokine production. This combination is being evaluated primarily for the prophylaxis and treatment of graft-versus-host disease (GVHD) in patients undergoing allogeneic hematopoietic cell transplantation, with the aim of improving immunosuppressive efficacy and safety profiles compared to standard regimens[5][1][3].
- Other names
- ItacitinibINCB039110INCB-039110INCB 039110Itacitinib in combination with calcineurin inhibitors
02
Targets
JAK1 (Janus kinase 1)CN (Calcineurin)
Beyond the preview
Go deeper on itacitinib + calcineurin inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on itacitinib + calcineurin inhibitor.